EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptor antagonist, in guinea pig models of allergic rhinitis.

Akihiro Kamiya, Tomohiko Sekioka, Masabumi Minami

Journal of Pharmacological Sciences · 2026

DOI: 10.1016/j.jphs.2026.02.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacological Sciences, 2026. Verfasst von Akihiro Kamiya und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Neurology, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka, 618-8585, Japan. Electronic address: a.kami…. Hauptthemen laut MEDLINE: Receptors, Leukotriene, Leukotriene Antagonists, Rhinitis, Allergic. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ono Pharmaceutical Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the anti-rhinitic effects of ONO-6950, a novel dual antagonist of cysteinyl leukotriene 1 (CysLT1) and 2 (CysLT2) receptors, in guinea pig models of allergic rhinitis. First, in a conventional allergic rhinitis model without S-hexyl glutathione (S-hexyl GSH), both ONO-6950 (3 mg/kg, orally (p.o.)) and montelukast (0.3, 1, or 3 mg/kg, p.o.), a selective CysLT1 antagonist, significantly suppressed the increases in nasal airway resistance and inflammatory cell infiltration induced by ovalbumin (OVA) challenge, with comparable efficacy. Subsequently, in a model with S-hexyl GSH treatment to inhibit LTC4 metabolism and enhance CysLT2 receptor-mediated responses, ONO-6950 (0.3, 1, or 3 mg/kg, p.o.) dose-dependently and almost completely inhibited both immediate and late increases in nasal airway resistance and inflammatory cell infiltration, whereas montelukast showed only partial or negligible inhibition. These results indicate that ONO-6950 is effective against both CysLT1-and CysLT2-mediated rhinitic responses, and may offer a novel therapeutic option for patients with allergic rhinitis, particularly in cases refractory to CysLT1-selective antagonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, LeukotrieneLeukotriene AntagonistsRhinitis, AllergicAnimalsGuinea PigsQuinolinesDisease Models, AnimalAcetatesCyclopropanesSulfidesDose-Response Relationship, DrugMaleOvalbuminLeukotriene C4Airway ResistanceFemaleCyclohexanecarboxylic AcidsPhthalic Acids

Stichwörter der Autor:innen

Allergic rhinitisCysLT(1)CysLT(2)Guinea pig modelONO-6950

Substanzen

Receptors, LeukotrieneLeukotriene AntagonistsQuinolinesmontelukastAcetatesCyclopropanesleukotriene D4 receptorSulfidescysteinyl leukotriene receptor 2Ovalbumin

Autor:innen und Institutionen

  • Research Center of Neurology, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka, 618-8585, Japan. Electronic address: a.kamiya@ono-pharma.com.
  • Medical Writing Office, Ono Pharmaceutical Co., Ltd., 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, 541-8564, Japan.
  • Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo Nishi 6-chome, Kita-ku, Sapporo, 060-0812, Japan.

Förderung

  • Ono Pharmaceutical Co Ltd

Zitieren

APA

Kamiya, A., Sekioka, T., & Minami, M. (2026). Effect of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptor antagonist, in guinea pig models of allergic rhinitis. Journal of Pharmacological Sciences. https://doi.org/10.1016/j.jphs.2026.02.005

Vancouver

Kamiya A, Sekioka T, Minami M. Effect of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptor antagonist, in guinea pig models of allergic rhinitis. Journal of Pharmacological Sciences. 2026. doi:10.1016/j.jphs.2026.02.005

BibTeX
@article{Kamiya2026,
  author = {Kamiya, Akihiro and Sekioka, Tomohiko and Minami, Masabumi},
  title = {Effect of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptor antagonist, in guinea pig models of allergic rhinitis},
  journal = {Journal of Pharmacological Sciences},
  year = {2026},
  doi = {10.1016/j.jphs.2026.02.005}
}
Kostenlos starten →